Posted in

Euglycemic DKA in Pregnancy: A Critical Clinician’s Guide

•Posted inObstetrics and Gynaecology

Diabetic ketoacidosis (DKA) is a severe, life-threatening complication of diabetes mellitus. Euglycemic DKA, a dangerous variant, presents unique diagnostic and therapeutic hurdles in pregnant patients. Consequently, pregnancy’s physiological adaptations, which include increased placental glucose consumption and relative insulin resistance, significantly heighten the risk for this condition. Therefore, clinicians must maintain a high index of suspicion. Current data suggests that up to 35% of DKA cases in gestation show euglycemia, confirming its growing relevance in obstetric medicine. Timely diagnosis and intervention are essential to mitigate the serious adverse maternal and fetal outcomes associated with this metabolic crisis.

Pathophysiology Unique to Euglycemic DKA

During pregnancy, a number of metabolic factors conspire to lower the threshold for ketosis. First, pregnancy itself is a ketogenic state. Moreover, the placental unit increases glucose utilization, resulting in lower maternal plasma glucose levels compared to non-pregnant DKA. Because of this high fetal and placental demand for glucose, the maternal body enters a state of relative starvation, even with normal food intake. This condition forces the body to rely on lipolysis for energy. The resulting elevation in free fatty acids then promotes severe ketogenesis. Thus, a patient can have profound ketosis and metabolic acidosis (pH <7.3, HCO3 <18 mEq/L) while blood glucose remains below 200 mg/dL.

Diagnosis of Euglycemic DKA in the Gravid Patient

The clinical presentation of Euglycemic DKA often mimics common pregnancy symptoms, which further complicates the diagnosis. Nausea, vomiting, and abdominal pain are frequent complaints, but clinicians might attribute these to hyperemesis gravidarum. Therefore, always confirm the diagnosis by measuring serum or urine ketones, especially in diabetic patients presenting with these symptoms. The primary diagnostic criteria include the presence of ketonemia or ketonuria alongside high anion gap metabolic acidosis. Glucose levels may be near-normal, which is why reliance on a blood sugar value alone is misleading. You must remember to conduct a thorough evaluation, including arterial blood gas analysis and electrolyte panels, for every pregnant patient with suspected DKA.

Critical Management Strategies

Managing this condition requires an aggressive, multidisciplinary approach to ensure the best possible outcomes. The cornerstone of therapy involves prompt volume resuscitation using intravenous crystalloids, typically Normal Saline, to correct dehydration. Furthermore, you must initiate intravenous insulin therapy immediately to halt ketogenesis. Because the patient is euglycemic, one must simultaneously administer dextrose-containing fluids (D5W or D10W) to prevent hypoglycemia while continuing the full-dose insulin infusion (0.1 units/kg/hr) required to resolve the acidosis. Consequently, careful glucose and electrolyte monitoring is mandatory. Potassium replacement is also crucial since DKA correction increases the risk of hypokalemia. Finally, continuous fetal heart rate monitoring is paramount, as fetal hypoxia and acidosis are common complications of maternal DKA.

Frequently Asked Questions

Q1: Why are pregnant women more susceptible to Euglycemic DKA?

Q1: Why are pregnant women more susceptible to Euglycemic DKA?

Due to the hormonal environment of pregnancy, especially in the second and third trimesters, pregnant patients experience an increased state of insulin resistance and higher metabolic demands. Additionally, the placenta and fetus consume significant amounts of glucose, keeping the mother’s blood sugar levels lower even as her body shifts into a state of lipolysis and ketosis. This combination of factors lowers the threshold for DKA at normal glucose concentrations.

Q2: What is the primary difference in treatment for Euglycemic DKA versus standard DKA?

Q2: What is the primary difference in treatment for Euglycemic DKA versus standard DKA?

The core components—intravenous fluids, IV insulin, and electrolyte correction—remain the same. However, the key difference is the early initiation of dextrose-containing fluids (D5W or D10W) alongside the insulin infusion. This ensures ketogenesis is halted by the insulin while preventing treatment-induced hypoglycemia, which is a significant risk when a patient presents with a normal or near-normal blood glucose level.

References

  1. Rowe JC et al. Diagnosis and Management of Euglycemic Diabetic Ketoacidosis in Pregnancy. Obstet Gynecol. 2025 Dec 11. doi: 10.1097/AOG.0000000000006143. PMID: 41380162.
  2. Alqahtani SF. Diagnosis and Management of Euglycemic Diabetic Ketoacidosis in a Young Pregnant Woman with Type 1 Diabetes Mellitus. Opast Publishing Group. 2018 Mar 15.
  3. Keel B, Gomez L. Euglycemic Diabetic Ketoacidosis in Pregnancy. MCN Am J Matern Child Nurs. 2025 Nov-Dec;50(6):350-356. doi: 10.1097/NMC.0000000000001145. PMID: 40811481.